Tirzepatide may quiet hunger, while nausea is common.

Hunger may ease before weight begins to fall

You may first notice that food no longer takes up so much thought. In obesity studies, people later lost 15-20% of body weight over 72 weeks, while people with type 2 diabetes also had lower blood sugar.

Nausea was most common while the dose rose. Constipation and diarrhea were also common, and roughly one person in four to one in two reported nausea at each step.

The FDA warning began with tumors in one kind of thyroid cell in rodents. Human studies haven't confirmed that harm, but FDA instructions rule out tirzepatide after a rare thyroid cancer that starts in those cells.

That warning also covers a family history of the cancer. It also covers MEN type 2, a family illness that may bring growths in glands that make hormones. Gallbladder trouble also happened more often, so your doctor needs your health history to weigh the risk.

Users report both welcome changes and rough weeks

These accounts came from patient groups, interviews after studies, and safety reports sent after the drug was in use. Researchers haven't tested these claims in a controlled study, so they aren't trial findings.

The words often and sometimes describe how often a comment appeared in those places. They don't tell you your chance of having the same result.

Changes users liked

Hunger took up less thought — often heard. People said meal plans, snacks, and the next bite faded into the background. In talks after SURMOUNT studies, 79-91% put a smaller appetite among their main gains.

Daily energy rose — heard quite often. About 62-79% said they felt livelier as weight came off. Others felt worn out for the first two to four weeks, then felt their energy return.

Mood or confidence lifted — heard quite often. In similar talks, 47-55% said one or both improved. A few written patient reports also showed lower depression scores as weight fell.

Blood tests improved — heard sometimes. Some users said their tests showed improved sugar and cholesterol tests, plus lower blood fats, along with less need for insulin. A few noticed the change within the first several months.

Sleep felt deeper — heard sometimes. Users mentioned falling asleep sooner and feeling more rested in the morning. Some with sleep apnea said a breathing machine that sends air through a face mask needed less pressure, or was stopped after major weight loss.

Knees, hips, or backs hurt less — heard sometimes. Some users said carrying fewer pounds eased sore joints. Walking and bending then took less effort for them.

Problems users described

Nausea followed a dose rise — often heard. About 25-50% mentioned nausea in community accounts and safety reports. It often peaked in week one or week two, then faded over the next several weeks.

Constipation and loose stools took turns — often heard. A person might go several days without a bowel movement, then have diarrhea. The swing often calmed as the stomach adjusted to moving food more slowly.

The shot left redness, pain, or a bruise — often heard. In the FDA's public safety report system, these were among the most common injection complaints, not necessarily the most severe. Users said moving the shot site helped, but no trial has tested that claim.

The scale paused for weeks — often heard. Users often placed the pause around months three, four, five, and six. Clinicians said a flat spell can be part of weight loss.

Strength left with some fat — heard sometimes. Some users worried that muscle was shrinking too. Study scans suggest 25-30% of the weight lost came from muscle, bone, water, and other non-fat tissue.

Hair began to thin — heard sometimes. Shedding tended to appear three to six months after starting and could follow fast weight loss. Studies recorded it in 4-5% on tirzepatide and 1% on placebo, an inactive shot.

Food tasted odd — heard sometimes. A metal taste could appear, or an old favorite could suddenly seem far too sweet. The change sometimes faded with time, or once doctors stopped raising the dose.

Burps smelled like eggs — heard sometimes. The cause may be food held in your stomach for longer. Later safety reports put these burps at about 3-5% of users.

Stomach trouble leads the risks, with thyroid and gallbladder cautions

The risks below come from FDA instructions and published papers. Each item says whether the risk was first seen in rodents, patients, or several studies read together.

Nausea and bowel trouble rise with the dose. Across 13 controlled studies, less appetite, nausea, constipation, diarrhea, and vomiting showed up more than in the inactive-shot group among people whose records showed obesity, not diabetes ^[14].

Half of the stomach and bowel reports reached the FDA system by about 16 days, and most arrived within the first three months ^[15]. Most trouble wasn't severe in most people, yet it caused most drug stoppages.

The thyroid warning began in rodents: tumors grew in one kind of thyroid cell more often at higher doses and after longer use. Human studies haven't found the same danger.

The label bars tirzepatide after a rare thyroid cancer that starts in those cells, or a family history of it. Tirzepatide is also ruled out for MEN 2, short for Multiple Endocrine Neoplasia type 2, a family illness that may lead to growths in glands that make hormones ^[16][17].

Gallbladder and bile-duct illness happened more often. A review of nine controlled studies covering 9,871 people found more trouble with tirzepatide than with comparison care ^[18].

The researchers used a 95% range, a way to show how much doubt remained, and the whole range still pointed to added risk. Another review of 12 studies found more combined problems and more gallstones ^[19].

Gallstones may follow a quick drop in weight. The papers couldn't tell how much of the added risk came from the drug itself.

A swollen pancreas remains an open question. Nine controlled studies left the question open, because the 95% range stretched from fewer cases to more ^[18].

Researchers also looked back at similar patients who had suffered pancreatitis before. During five years, repeat attacks were less common among tirzepatide users, but a look back like this can't prove the drug prevented them ^[20].

Other diabetes drugs can make your sugar fall too far. For people with type 2 diabetes, tirzepatide by itself is less apt to drive sugar too low. Low sugar becomes more likely when it's paired with a sulfonylurea, a pill that makes the pancreas release insulin, or with insulin itself ^[16][21].

A procedure may begin while food still sits in the stomach. Tirzepatide keeps food in your stomach longer. Your body needs about a 5-day span to remove half of the drug.

Upper digestive scopes have found food even after patients fasted. During deep sleep for a procedure, a person could breathe those stomach contents into the lungs ^[22][23].

The event is rare, but your care team needs the drug name before any procedure. They'll decide whether the timing or preparation needs to change.

Some lost weight is muscle and other non-fat tissue. A SURMOUNT-1 scan put that share near 25%, including muscle, bone, and water ^[12].

Across other work, the middle share tied to muscle was about 28% ^[13]. One review compared the pace with a decade or more of aging, though no one yet knows what it means for strength years later ^[24].

The birth-control pill may fail more easily for a short time. Because the stomach slows, the FDA label names condoms or another method not taken by mouth for four weeks after starting and for four weeks after each dose increase ^[16][23].

Stopping tirzepatide often brings some pounds back. In SURMOUNT-4, the group switched to placebo regained weight, while the group continuing tirzepatide lost more ^[25][26].

The result favors ongoing care instead of a short course. It doesn't show what will happen after every person stops.

Side effects caused more people to stop tirzepatide. Across three direct studies against dulaglutide, a GLP-1 drug that copies one gut hormone, the stopping rate was 32% higher ^[27].

That percentage compares two stopping rates; it doesn't mean that many out of every hundred people stopped. Federal reports also named giving the wrong dose as the most common mistake ^[28].

All-over hair thinning can follow a quick drop in weight. Doctors link most of the shedding to the strain of losing quickly, and it often ends after weight settles ^[29].

The drug grew from an idea about two gut hormones

Researchers knew that GIP and GLP-1 are two hormones made in your bowel. Each helps your pancreas move insulin into your blood after food.

They wanted to know if one medicine using both could outperform a medicine based only on GLP-1 ^[1][30]. Eli Lilly first reported tirzepatide in 2018.

The drug is a 39-amino-acid chain, meaning linked protein pieces, with an added fat molecule that helps it stay longer. In mice, tirzepatide cut sugar and body weight by more than a medicine based on GLP-1.

Then an early safety study in 142 people found that one weekly shot kept useful drug levels through the week ^[1]. Tests on cells kept alive in dishes found that the GIP effect was stronger than the GLP-1 effect.

That lab finding couldn't predict a person's weight or blood sugar ^[2]. Larger studies in people came next.

SURPASS followed type 2 diabetes, while SURMOUNT followed obesity. Later direct tests favored tirzepatide over semaglutide, another one-hormone drug.

FDA approval for type 2 diabetes came in May 2022 ^[16]. November 2023 brought FDA clearance for ongoing weight care ^[31], then sleep apnea use in adults living with obesity.

SUMMIT found fewer heart-disease deaths or times when heart failure got worse ^[32]. SURMOUNT-OSA found fewer stopped or slowed breaths during sleep ^[33].

SYNERGY-NASH found that a serious liver illness caused by built-up fat cleared from some liver samples without worse scarring ^[34]. The paper examined liver tissue rather than symptoms the patients noticed.